BP11139 PLGA 65:35, Hydroxyl Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa

PLGA 65:35, Hydroxyl Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Description

This polymer, known chemically as poly(lactic-co-glycolic acid), features a 65:35 ratio of lactic to glycolic acid units with hydroxyl end groups that facilitate subsequent reactions. The intrinsic viscosity of 0.08 dl/g and molecular weight around 5 kDa are critical for defining its degradation rate. These technical parameters ensure that the polymer undergoes predictable hydrolysis, making it suited for biomedical implants, controlled drug release, and other applications requiring temporal material resorption.

PLGA 65:35, Hydroxyl Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Applications

1.         Healthcare
   - Used as a drug delivery carrier in implantable devices to achieve regulated therapeutic release by leveraging controlled hydrolysis and predictable degradation kinetics.

2.         Tissue Engineering
   - Applied as a scaffold in regenerative medicine to enhance cell proliferation by leveraging its biocompatibility and resorption characteristics.

PLGA 65:35, Hydroxyl Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Packing

The PLGA powder is packaged in sealed, inert atmosphere containers with moisture barrier materials to prevent exposure to humidity. It is stored under temperature-controlled and dark conditions to minimise photo-oxidation and premature hydrolysis. Secondary anti-contamination packaging further secures the material during transport. Custom packaging options, including specialised labels and controlled packing formats, are available to suit specific storage and shipping requirements.

Additional Information

Poly(lactic-co-glycolic acid) materials play a significant role in biomedical and pharmaceutical fields due to their degradability and biocompatibility. The copolymer degrades through hydrolytic cleavage, a process that can be precisely tuned by adjusting the monomer ratio and molecular weight, making it suitable for applications requiring predictable material resorption.

Understanding the degradation behaviour of PLGA is essential for designing medical devices and drug delivery systems. The controlled breakdown of the polymer minimises adverse tissue reactions and supports its application in implants and regenerative scaffolds, thereby contributing to its extensive use in therapeutic technologies.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.